| Literature DB >> 31560818 |
Yong Huang1, Lifeng Jiang2, Haoyu Yang1, Lidong Wu2, Nanwei Xu1, Xindie Zhou1, Jin Li3.
Abstract
Excessive activation of the Wnt signalling pathway in the articular cartilage is demonstrated to be related to the onset and severity of osteoarthritis (OA). However, few studies have investigated the association between variants in Wnt-pathway-related genes and the risk of OA by searching Pubmed and EMBASE. Totally, 471 knee OA patients and 532 controls were recruited from three hospitals to evaluate the associations of five genetic variants (rs61735963, rs2908004, rs10795550, rs1799986 and rs1127379) with the risk of knee OA. These polymorphisms were genotyped through polymerase chain reaction and Sanger sequencing. Genetic risk scores (GRSs) were calculated to evaluate the combined effect of these genetic variants. No significant association was found between OA risk and polymorphisms (rs61735963, rs10795550 or rs1127379). However, WNT16 rs2908004 polymorphism was correlated with a decreased risk of OA, especially among females, smokers, non-drinkers and individuals with age < 60 years or BMI ≥ 25. This SNP was also associated with Kellgren-Lawrence grade and CRP. Similarly, LRP1 rs1799986 polymorphism decreased the risk of OA among males, smokers, drinkers and individuals with age < 60 years or BMI ≥ 25. TT genotype was more frequent in the group of VAS ≥ 6 versus VAS < 6. A low GRS was positively correlated with a decreased risk of OA. In addition, rs2908004 or rs1799986 polymorphism reduces the expression of WNT16 or LRP1. In conclusion, two SNPs (rs2908004 and rs1799986) are associated with the decreased risk of OA by regulating the Wnt pathway.Entities:
Keywords: Wnt; bioinformatics analysis; genetic risk score; knee osteoarthritis; polymorphism
Mesh:
Substances:
Year: 2019 PMID: 31560818 PMCID: PMC6850928 DOI: 10.1111/jcmm.14696
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Characteristics of included studies
| Author and year | Type of study | Country | Sample size | Genotyping method | Polymorphism | QAS |
|---|---|---|---|---|---|---|
| Loughlin2004 | Family case‐control | UK |
OA/control | PCR‐RFLP | TNFAIP6 rs1046668; ITGA6 rs2737085 rs10209072; FRZB rs288326 rs7775 | 8 |
| Urano2007 | Case‐only | Japan |
Spinal OA | TaqMan | W1SP1 2364A/G | 7 |
| Kerkhof2008 | Cohort | Netherlands | Hip/knee/hand OA 2507 | TaqMan | FRZB rs288326 rs7775; LRP5 Ala1330val; LRP6 lle1062val | 8 |
| Urano2008 | Case‐only | Japan |
Spinal OA | TaqMan | LRP5 Q89R | 7 |
| Valdes2009 | Case‐control | UK |
Knee/hip OA/control | PCR | ANP32A rs7164503 | 7 |
| Lamas2010 | Case‐control | Spain |
OA/control | N/A | COL10A1 rs11965969 | 7 |
| Gao2010 | Family cohort | China |
Osteoarthritis | TaqMan | FZRB rs643399 rs409238 rs288324 rs4666865 | 7 |
| Leijten2012 | Cohort | Netherlands |
OA | N/A |
GREM1 rs1881537 rs921510 rs4779584 rs1258726 rs12593365 | 8 |
| Baker‐LePain2012 | Case‐control | USA |
Hip OA/controls | PCR | FRZB (rs288326 rs7775) | 9 |
| Garca‐Ibarbia2013 | Case‐only | Spain |
Hip fractures/hip OA | Sequencing |
WNT4 (rs7526484 rs2235526 rs10917158) | 9 |
| Garca‐Ibarbia2013 | Case‐control | Spain |
Hip/knee OA/control | TaqMan |
WNT1 (rs11610885 rs10878228 rs7397906 rs6581609 rs1900292); WNT10A (rs3806557 rs10177996 rs2385199) | 10 |
| Garca‐Ibarbia2017 | Case‐only | Spain |
Hip OA/knee OA | TaqMan | WNT16 rs2707466 rs2908004 | 8 |
| Fernandez‐Torres2018 | Case‐control | Mexico |
Knee OA/control | TaqMan | LRP6 rs12314259; SOST rs851054; FMN2 rs986690; FRZB rs409328; COL11A1 rs265977 | 8 |
Positive sites on the Wnt signalling pathway‐related genes
| SNP | Gene | Major/minor allele | MAF | Location | Results | Country |
|---|---|---|---|---|---|---|
| Rs2353525 | BCL9 | T/G | 0.4293/1250 | Intron | Risk | Spain |
| Rs12341259 | LRP6 | C/T | 0.0094/47 | Intron | Protect | Mexico |
| Rs851054 | SOST | C/A | 0.4441/2224 | Intron/3’‐UTR | Protect | Mexico |
| Rs986690 | FMN2 | G/A | 0.3203/1604 | Intron | Protect | Mexico |
| Rs409238 | FRZB | G/A | 0.4301/2154 | Intron | Risk | Mexico |
| Rs2615977 | COL11A1 | A/C | 0.2194/1099 | Intron | Risk | Mexico |
| Rs2707466 | WNT16 | C/T | 0.4970/2489 | Exon | Risk | Spain |
| Rs2929970 | WISP1 | G/A | 0.4441/2224 | 3’‐UTR | Risk | Japan |
| Rs41494349 | LRP5 | A/G | 0.0200/100 | Exon/promoter | Protect | Japan |
| Rs7164503 | ANP32A | T/C | 0.3816/1911 | Intron | Protect | UK |
| Rs12593365 | GREM1 | T/C | 0.2165/1084 | Exon | Protect | Netherlands |
| Rs2908004 | WNT16 | G/A | 0.4896/2452 | Exon | Protect | Spain |
Figure 1The protein interaction network of Wnt/β‐catenin pathway‐related genes
Figure 2Barplot of representative GO analysis of Wnt/β‐catenin pathway‐related genes. A, Biological process; B, cellular component; C, molecular function
Patient demographics and risk factors in osteoarthritis
| Variable | Cases (n = 471) | Controls (n = 532) |
|
|---|---|---|---|
| Age (y) | 57.87 ± 8.79 | 57.47 ± 9.25 | .482 |
| Sex | |||
| Male | 214 (45.4%) | 248 (46.6%) | .708 |
| Female | 257 (54.6%) | 284 (53.4%) | |
| BMI | 25.04 ± 3.95 | 24.92 ± 3.78 | .632 |
| Smoking | |||
| Yes | 201 (42.7%) | 244 (45.9%) | .310 |
| No | 270 (57.3%) | 288 (54.1%) | |
| Alcohol | |||
| Yes | 238 (50.5%) | 239 (44.9%) | .076 |
| No | 233 (49.5%) | 293 (55.1%) | |
| ESR | 11.52 ± 13.52 | – | – |
| CRP | 7.15 ± 15.67 | – | – |
| VAS | 7.92 ± 1.25 | – | – |
| Lequesnes’ index | 15.32 ± 1.88 | – | – |
| L/R knee OA | |||
| Left | 252 (53.5%) | – | – |
| Right | 219 (46.5%) | – | |
| Kellgren‐Lawrence grade | |||
| II | 65 (13.8%) | – | – |
| III | 198 (42.0%) | – | |
| IV | 208 (44.2%) | – | |
Abbreviations: BMI, body mass index; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale.
Logistic regression analysis of associations between polymorphisms and risk of osteoarthritis
| Genotype | Cases | Controls | OR (95% CI) |
| OR (95% CI) |
| ||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | |||||
| rs2908004 G/A | ||||||||
| GG | 158 | 33.6 | 138 | 26.0 | 1.00 | – | – | – |
| GA | 228 | 48.5 | 265 | 49.9 | 0.75 (0.57‐1.01) | 0.056 | 0.75 (0.57‐1.01) | 0.056 |
| AA | 84 | 17.9 | 128 | 24.1 |
|
|
|
|
| GA + AA | 312 | 66.4 | 393 | 74.0 |
|
|
|
|
| GG + GA | 386 | 82.1 | 403 | 75.9 | 1.00 | – | – | – |
| AA | 84 | 17.9 | 128 | 24.1 |
|
|
|
|
| G allele | 544 | 57.9 | 541 | 50.9 | 1.00 | – | – | – |
| A allele | 396 | 42.1 | 521 | 49.1 |
|
| – | – |
| rs10795550 T/C | ||||||||
| TT | 285 | 60.6 | 305 | 57.4 | 1.00 | – | – | – |
| TC | 162 | 34.5 | 195 | 36.7 | 0.89 (0.69‐1.16) | 0.404 | 0.90 (0.69‐1.17) | 0.418 |
| CC | 23 | 4.9 | 31 | 5.8 | 0.79 (0.45‐1.39) | 0.422 | 0.79 (0.45‐1.39) | 0.418 |
| TC + CC | 185 | 39.4 | 226 | 42.6 | 0.88 (0.68‐1.13) | 0.322 | 0.88 (0.68‐1.14) | 0.328 |
| TT + TC | 447 | 95.1 | 500 | 94.2 | 1.00 | – | – | – |
| CC | 23 | 4.9 | 31 | 5.8 | 0.83 (0.48‐1.44) | 0.505 | 0.83 (0.47‐1.44) | 0.498 |
| T allele | 732 | 77.9 | 805 | 75.8 | 1.00 | – | – | – |
| C allele | 208 | 22.1 | 257 | 24.2 | 0.89 (0.72‐1.10) | 0.273 | – | – |
| rs1127379 T/C | ||||||||
| TT | 120 | 25.6 | 146 | 27.5 | 1.00 | – | – | – |
| TC | 234 | 49.9 | 265 | 49.9 | 1.07 (0.80‐1.45) | 0.639 | 1.08 (0.80‐1.45) | 0.624 |
| CC | 115 | 24.5 | 120 | 22.6 | 1.18 (0.83‐1.67) | 0.368 | 1.18 (0.83‐1.68) | 0.358 |
| TC + CC | 349 | 74.4 | 385 | 72.5 | 1.11 (0.84‐1.47) | 0.485 | 1.11 (0.84‐1.47) | 0.471 |
| TT + TC | 354 | 75.5 | 411 | 77.4 | 1.00 | |||
| CC | 115 | 24.5 | 120 | 22.6 | 1.12 (0.84‐1.50) | 0.441 | 1.12 (0.84‐1.51) | 0.436 |
| T allele | 474 | 50.5 | 557 | 52.4 | 1.00 | – | – | – |
| C allele | 464 | 49.5 | 505 | 47.6 | 1.08 (0.91‐1.29) | 0.392 | – | – |
| rs61735963 C/T | ||||||||
| CC | 403 | 85.7 | 444 | 83.6 | 1.00 | – | – | – |
| CT | 64 | 13.6 | 83 | 15.6 | 0.85 (0.60‐1.21) | 0.359 | 0.85 (0.60‐1.21) | 0.358 |
| TT | 3 | 0.6 | 4 | 0.8 | 0.82 (0.18‐3.71) | 0.801 | 0.82 (0.18‐3.68) | 0.793 |
| CT + TT | 67 | 14.3 | 87 | 16.4 | 0.85 (0.60‐1.20) | 0.345 | 0.85 (0.60‐1.20) | 0.348 |
| CC + CT | 467 | 99.4 | 527 | 99.2 | 1.00 | – | – | – |
| TT | 3 | 0.6 | 4 | 0.8 | 0.85 (0.19‐3.80) | 0.827 | 0.84 (0.19‐3.77) | 0.819 |
| C allele | 870 | 92.6 | 971 | 91.4 | 1.00 | – | – | – |
| T allele | 70 | 7.4 | 91 | 8.6 | 0.86 (0.62‐1.19) | 0.357 | – | – |
| rs1799986 C/T | ||||||||
| CC | 287 | 61.1 | 282 | 53.1 | 1.00 | – | – | – |
| CT | 160 | 34.0 | 203 | 38.2 | 0.77 (0.59‐1.01) | 0.055 | 0.77 (0.59‐1.01) | 0.056 |
| TT | 23 | 4.9 | 46 | 8.7 |
|
|
|
|
| CT + TT | 183 | 38.9 | 249 | 46.9 |
|
|
|
|
| CC + CT | 447 | 95.1 | 485 | 91.3 | 1.00 | – | – | – |
| TT | 23 | 4.9 | 46 | 8.7 |
|
|
|
|
| C allele | 734 | 78.1 | 767 | 72.2 | 1.00 | – | – | – |
| T allele | 206 | 21.9 | 295 | 27.8 |
|
| – | – |
Bold values are statistically significant (P < .05).
The genotyping was successful in 470 cases and 531 controls for rs2908004, rs10795550, rs61735963 and rs1799986; the genotyping was successful in 469 cases and 531 controls for rs1127379.
Adjust for age and sex.
Stratified analyses between rs2908004/rs1799986 polymorphisms and the risk of osteoarthritis
| Variable | Case/control | Heterozygous model | Homozygous model | Recessive model | Dominant model | ||
|---|---|---|---|---|---|---|---|
| Rs2908004 | GG | GA | AA | GA vs. GG | AA vs.GG | AA vs. GA + GG | AA + GA vs.GG |
| Sex | |||||||
| Male | 69/71 | 108/121 | 36/56 | 0.93 (0.61‐1.41); 0.721 | 0.66 (0.39‐1.13); 0.129 | 0.69 (0.44‐1.11); 0.124 | 0.84 (0.57‐1.25); 0.397 |
| Female | 89/67 | 120/144 | 48/72 |
|
| 0.67 (0.45‐1.02); 0.060 |
|
| Smoking | |||||||
| Yes | 71/69 | 104/121 | 26/53 | 0.84 (0.55‐1.29); 0.426 |
|
| 0.73 (0.49‐1.09); 0.125 |
| No | 87/69 | 124/144 | 58/75 | 0.68 (0.46‐1.02); 0.060 |
| 0.78 (0.53‐1.16); 0.216 |
|
| Alcohol | |||||||
| Yes | 76/62 | 111/124 | 45/53 | 0.68 (0.45‐1.04); 0.073 | 0.64 (0.38‐1.08); 0.093 | 0.81 (0.52‐1.27); 0.366 |
|
| No | 82/76 | 117/141 | 39/75 | 0.83 (0.56‐1.24); 0.362 |
|
| 0.72 (0.49‐1.06); 0.092 |
| Age (y) | |||||||
| <60 | 97/80 | 123/157 | 54/72 |
|
| 0.80 (0.54‐1.20); 0.284 |
|
| ≥60 | 61/58 | 105/108 | 30/56 | 0.92 (0.59‐1.45); 0.731 |
|
| 0.78 (0.51‐1.20); 0.259 |
| BMI | |||||||
| <25 | 74/66 | 119/139 | 45/61 | 0.77 (0.51‐1.16); 0.212 | 0.66 (0.40‐1.09); 0.107 | 0.78 (0.51‐1.20); 0.260 | 0.74 (0.50‐1.09); 0.123 |
| ≥25 | 84/72 | 109/126 | 39/67 | 0.74 (0.49‐1.11); 0.149 |
|
|
|
Bold values are statistically significant (P < .05).
The associations between rs2908004/rs1799986 polymorphism and clinical characteristics of osteoarthritis
| Characteristics | Genotype distributions | |||
|---|---|---|---|---|
| Rs2908004 | GG | GA | AA | GA + AA |
| ESR | ||||
| ≥10/<10 | 61/97 | 97/131 | 32/52 | 129/183 |
| OR (95%CI); | 1.0 (reference) | 1.18 (0.78‐1.78); .439 | 0.98 (0.57‐1.69); .938 | 1.12 (0.76‐1.65); .568 |
| CRP | ||||
| ≥25/<25 | 15/143 | 10/218 | 3/81 | 13/299 |
| OR (95%CI); | 1.0 (reference) | 0.44 (0.19‐1.00); .054 | 0.35 (0.10‐1.26); .095 |
|
| K‐L grade | ||||
| Ⅲ + Ⅳ/Ⅰ + Ⅱ | 133/25 | 170/58 | 59/25 | 229/83 |
| OR (95%CI); | 1.0 (reference) |
|
|
|
| VAS | ||||
| ≥6/<6 | 151/7 | 213/15 | 77/7 | 290/22 |
| OR (95%CI); | 1.0 (reference) | 0.66 (0.26‐1.65); .371 | 0.51 (0.17‐1.51); .216 | 0.61 (0.26‐1.46); .265 |
| Lequesnes’ index | ||||
| ≥12/<12 | 153/5 | 218/10 | 81/3 | 299/13 |
| OR (95%CI); | 1.0 (reference) | 0.71 (0.24‐2.13); .542 | 0.88 (0.21‐3.79); .866 | 0.75 (0.26‐2.15); .593 |
Bold values are statistically significant (P < .05).
The association of genetic risk score of Wnt signalling pathway‐related genes with risk of osteoarthritis
| Variable | Case (n = 471) | Control (n = 532) | OR (95% CI) |
| Adjusted OR (95% CI) |
|
|---|---|---|---|---|---|---|
| Weighted GRS | N (%) | N (%) | ||||
| First (−0.5,0) | 311 (66.9%) | 287 (53.9%) | 1 | 1 | ||
| Second (−1.0, −0.5) | 149 (31.6%) | 216 (40.6%) |
|
|
|
|
| Third (−1.5, −1.0) | 5 (1.1%) | 24 (4.5%) |
|
|
|
|
The genotyping was successful in 465 cases and 527 controls. Adjusted for sex and age. Bold values are statistically significant (P < .05).
Figure 3The mRNA expression by the genotypes of two polymorphisms among cases and controls. (A) WNT16 rs2908004 polymorphism; (B) LRP1 rs1799986 polymorphism